dihydroxyphenylalanine has been researched along with Anochlesia in 29 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The loaded gel was administered in different doses and dosing regimens to Parkinsonian rats, and the catalepsy score and striatal DA levels were assessed." | 1.42 | Potential efficacy of dopamine loaded-PVP/PAA nanogel in experimental models of Parkinsonism: possible disease modifying activity. ( Abd El-Rehim, HA; El-Ghazaly, MA; Rashed, ER, 2015) |
| "Aripiprazole did not inhibit physostigmine- or norepinephrine-induced lethality in rats." | 1.32 | Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. ( Altar, CA; Burris, KD; Hirose, T; Kikuchi, T; Kitagawa, H; Miwa, T; Nabeshima, T; Uwahodo, Y; Yamada, S, 2004) |
| "Compound 28 induced catalepsy at 10 times higher dose than that required for the antagonism of APO-induced stereotypy (ED50 value of 7." | 1.30 | Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. ( Kikuchi, T; Kurahashi, N; Nishi, T; Oshiro, Y; Sato, S; Tanaka, T; Tottori, K; Uwahodo, Y, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (75.86) | 18.7374 |
| 1990's | 4 (13.79) | 18.2507 |
| 2000's | 2 (6.90) | 29.6817 |
| 2010's | 1 (3.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rashed, ER | 1 |
| Abd El-Rehim, HA | 1 |
| El-Ghazaly, MA | 1 |
| NAKAJIMA, H | 1 |
| GRANDJEAN, JL | 1 |
| LHUILLIER, J | 1 |
| THUILLIER, J | 1 |
| Galenko-Yaroshevskii, PA | 1 |
| Gurskaya, EV | 1 |
| Chikobava, EA | 1 |
| Sukoyan, GV | 1 |
| Hirose, T | 2 |
| Uwahodo, Y | 3 |
| Yamada, S | 1 |
| Miwa, T | 2 |
| Kikuchi, T | 3 |
| Kitagawa, H | 1 |
| Burris, KD | 1 |
| Altar, CA | 1 |
| Nabeshima, T | 1 |
| Mjörndal, T | 1 |
| Persson, SA | 1 |
| Tottori, K | 2 |
| Oshiro, Y | 2 |
| Morita, S | 1 |
| Patacchioli, FR | 1 |
| Di Grezia, R | 1 |
| Angelucci, L | 1 |
| Sato, S | 1 |
| Kurahashi, N | 1 |
| Tanaka, T | 1 |
| Nishi, T | 1 |
| Voith, K | 1 |
| Nomura, Y | 1 |
| Segawa, T | 1 |
| Ahlenius, S | 1 |
| Wijkström, A | 1 |
| Kerkman, DJ | 1 |
| Ackerman, M | 1 |
| Artman, LD | 1 |
| MacKenzie, RG | 1 |
| Johnson, MC | 1 |
| Bednarz, L | 1 |
| Montana, W | 1 |
| Asin, KE | 1 |
| Stampfli, H | 1 |
| Kebabian, JW | 1 |
| Sacks, OW | 1 |
| Kohl, M | 1 |
| Klawans, HL | 1 |
| Goetz, C | 1 |
| Westheimer, R | 1 |
| Johnson, AM | 1 |
| Vigouret, JM | 1 |
| Loew, DM | 1 |
| Maj, J | 3 |
| Przegaliński, E | 1 |
| Kapturkiewicz, Z | 1 |
| Sarnek, J | 1 |
| Hatch, RC | 1 |
| Kuschinsky, K | 2 |
| Hornykiewicz, O | 2 |
| Cashin, CH | 1 |
| Sutton, S | 1 |
| Zetler, G | 1 |
| Thörner, R | 1 |
| Nakamura, K | 1 |
| Kuntzman, R | 1 |
| Maggio, A | 1 |
| Conney, AH | 1 |
| Gouret, C | 1 |
| Raynaud, G | 1 |
| Papeschi, R | 1 |
| Randrup, A | 1 |
| Sowińska, H | 1 |
| Baran, L | 1 |
| Cools, AR | 1 |
| Fog, R | 1 |
| Pakkenberg, H | 1 |
| Loizzo, A | 1 |
| De Carolis, AS | 1 |
| Longo, VG | 1 |
1 review available for dihydroxyphenylalanine and Anochlesia
| Article | Year |
|---|---|
Pathophysiology of schizophrenia and the striatum.
Topics: Adult; Amphetamine; Animals; Basal Ganglia; Catalepsy; Caudate Nucleus; Dihydroxyphenylalanine; Dopa | 1972 |
28 other studies available for dihydroxyphenylalanine and Anochlesia
| Article | Year |
|---|---|
Potential efficacy of dopamine loaded-PVP/PAA nanogel in experimental models of Parkinsonism: possible disease modifying activity.
Topics: Acrylic Resins; Animals; Catalepsy; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Male; | 2015 |
[EXPERIMENTAL ANTAGONISM OF CHLORPROMAZINE AND THIORIDAZINE IN RELATION TO CERTAIN EFFECTS OF LYSERGIDE].
Topics: 5-Hydroxytryptophan; Catalepsy; Chlorpromazine; Dihydroxyphenylalanine; Humans; Hypothermia; Lysergi | 1964 |
Anticataleptic effect of energostim during single treatment with trifluoperazine.
Topics: Animals; Antioxidants; Antipsychotic Agents; Catalepsy; Dihydroxyphenylalanine; Dopamine; Epinephrin | 2004 |
Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blepharoptosis; Catalepsy; Dihydroxyph | 2004 |
The relation between spiperone binding, behavioural changes, and in vivo tyrosine hydroxylation in the rat striatum.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Binding Sites; Catalepsy; Corpus Striatum; Di | 1983 |
7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Catalepsy; Corpus Striatu | 1995 |
Arginine-aspartate and haloperidol-induced neurobehavioral effects in the rat.
Topics: Animals; Antipsychotic Agents; Arginine; Aspartic Acid; Catalepsy; Corpus Striatum; Dihydroxyphenyla | 1996 |
Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Brain; Catalepsy; Dihydro | 1998 |
Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
Topics: Animals; Behavior, Animal; Catalepsy; Dihydroxyphenylalanine; Drug Synergism; Fluphenazine; Humans; | 1977 |
Muscarinic hyposensitivity in the developing rat pretreated with 6-hydroxydopa.
Topics: Animals; Atropine; Catalepsy; Dihydroxyphenylalanine; Dopamine; Female; Humans; Male; Motor Activity | 1978 |
Mixed agonist-antagonist properties of umespirone at neostriatal dopamine receptors in relation to its behavioral effects in the rat.
Topics: 5-Hydroxytryptophan; Animals; Behavior, Animal; Biogenic Monoamines; Brain Chemistry; Bridged Bicycl | 1992 |
A-69024: a non-benzazepine antagonist with selectivity for the dopamine D-1 receptor.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Benzazepines; Binding, Competitive; Catalepsy; Dihydroxyphe | 1989 |
L-dopa and oculogyric crises.
Topics: Catalepsy; Dihydroxyphenylalanine; Encephalitis, Arbovirus; Eye; Humans; Mental Disorders | 1970 |
Proceedings: CB 154 (2-bromo-alpha-ergokryptine, bromocriptin), a potential anti-Parkinson agent.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Brain; Bromine; Catalepsy; Dextroamphe | 1974 |
Disulfiram and the effect of catecholamines on neuroleptic-induced catalepsy in mice and rats.
Topics: Animals; Brain; Catalepsy; Chlorpromazine; Dihydroxyphenylalanine; Disulfiram; Drug Antagonism; Halo | 1967 |
The effect of L-dopa on neuroleptic-induced catalepsy.
Topics: Animals; Catalepsy; Chlorpromazine; Dihydroxyphenylalanine; Fenclonine; Fluphenazine; Humans; Male; | 1972 |
Ketamine catalepsy and anesthesia in dogs pretreated with antiserotonergic or antidopaminergic neuroleptics or with anticholinergic agents.
Topics: Anesthesia; Animals; Atropine; Catalepsy; Chlorpromazine; Dibenzothiepins; Dihydroxyphenylalanine; D | 1974 |
Effects of morphine on striatal dopamine metabolism: possible mechanism of its opposite effect on locomotor activity in rats and mice.
Topics: Animals; Apomorphine; Brain Chemistry; Catalepsy; Catechols; Caudate Nucleus; Chlorpromazine; Clonid | 1974 |
The effect of anti-Parkinson drugs on catalepsy induced by -methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine.
Topics: Amantadine; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Benztropine; Brain | 1973 |
Drug-induced catalepsy as influenced by psychostimulants, apomorphine, L-dopa, and yohimbine.
Topics: Amphetamine; Animals; Apomorphine; Catalepsy; Dihydroxyphenylalanine; Hallucinogens; Haloperidol; Hu | 1973 |
Decrease in morphine's analgesic action and increase in its cataleptic action by 6-hydroxydopamine injected bilaterally into caudate and putamen areas; partial restoration by L-DOPA plus decarboxylase inhibition.
Topics: Analgesics; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Brain Chemistry; Catalepsy; Cauda | 1973 |
[L-DOPA jumping test in mice: its use in the study of antagonistic psychotropic drugs].
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Dihydroxyphenylalanine; Drug Evaluation, Preclini | 1973 |
Catalepsy, sedation and hypothermia induced by alpha-methyl-p-tyrosine in the rat. An ideal tool for screening of drugs active on central catecholaminergic receptors.
Topics: Amantadine; Animals; Apomorphine; Behavior, Animal; Body Temperature; Brain Chemistry; Catalepsy; De | 1973 |
The effect of amantadine on motor activity and catalepsy in rats.
Topics: Amantadine; Animals; Brain; Catalepsy; Catecholamines; Chlorpromazine; Cocaine; Desipramine; Dihydro | 1972 |
Neurochemical correlates of the waltzing-shaker syndrome in the Varitint-waddler mouse.
Topics: Animals; Autoradiography; Behavior, Animal; Carbon Isotopes; Catalepsy; Dextroamphetamine; Dihydroxy | 1972 |
Morphine catalepsy in the rat: relation to striatal dopamine metabolism.
Topics: Animals; Apomorphine; Brain Chemistry; Catalepsy; Chlorpromazine; Corpus Striatum; Dihydroxyphenylal | 1972 |
Intracerebral lesions causing stereotyped behaviour in rats.
Topics: Amphetamine; Animals; Basal Ganglia; Behavior, Animal; Brain Injuries; Catalepsy; Catheterization; D | 1971 |
Studies on the central effects of bulbocapnine.
Topics: 5-Hydroxytryptophan; Animals; Aporphines; Catalepsy; Cats; Cerebral Cortex; Dihydroxyphenylalanine; | 1971 |